Pharmacodynamics and Pharmacokinetics of Cannabis (Marijuana); Therapeutic Potential for Psychiatric Disorders
dc.contributor.advisor | Pórszász, Róbert | |
dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.contributor.author | Urata, Miyako | |
dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
dc.contributor.opponent | Drimba, László | |
dc.contributor.opponent | Szentmiklósi, József András | |
dc.contributor.opponentdept | Kenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztály | hu_HU |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.date.accessioned | 2017-07-14T08:41:14Z | |
dc.date.available | 2017-07-14T08:41:14Z | |
dc.date.created | 2017-05-29 | |
dc.description.abstract | Phytocannabinoids, including delta9-THC, CBD and CBC, indicate their therapeutic potential for psychiatric disorders. Future studies should further investigate the pathophysiological and pharmacological approaches, followed by evidence-based clinical studies and accurate epidemiological data. Furthermore, investigation of cannabinoids should be compared against the therapeutic and adverse effects of available psychiatric medications, such as anti-depressant and the others. | hu_HU |
dc.description.course | általános orvos | hu_HU |
dc.description.courselang | magyar | hu_HU |
dc.description.degree | egységes, osztatlan | hu_HU |
dc.format.extent | 39 | hu_HU |
dc.identifier.uri | http://hdl.handle.net/2437/242582 | |
dc.language.iso | en | hu_HU |
dc.subject | psychiatric disorders | hu_HU |
dc.subject.dspace | DEENK Témalista::Pszichológia | hu_HU |
dc.title | Pharmacodynamics and Pharmacokinetics of Cannabis (Marijuana); Therapeutic Potential for Psychiatric Disorders | hu_HU |